Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law

Hoboken, NJ — January 18, 2011 — Anavex Life Sciences Corp. (“Anavex”, AVXL.OB) today commented on President Obama’s signing of the National Alzheimer’s Project Act (NAPA) into law.  The passage of this landmark legislation lays the foundation for the first coordinated national plan to overcome Alzheimer’s disease. “NAPAis the largest legislative victory in many years…

Alzheimer’s Weekly Names ANAVEX 2-73 the Number One Most Promising Trial Drug in Alzheimer’s Disease and Anavex’s Phase I Clinical Program as “Trial of the Year”

Hoboken, NJ — January 6, 2011 — Anavex Life Sciences Corp. (“Anavex”, AVXL.OB) announced today that ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.  The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer’s and following…

Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease

Meets major clinical development milestone for lead compound Hoboken, NJ — December 21, 2010 — Anavex Life Sciences Corp. (“Anavex”, AVXL:OB) announced today that it has filed the regulatory submission for ANAVEX 2-73  with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead…

ANAVEX 2-73: Journal of Psychopharmacology Publishes Anti-Amnesic and Neuroprotective Data Against Amyloid Toxicity For First of a New Class in Alzheimer’s Disease

Profile comparison to donepezil, citing greater potential benefits Califon, NJ – September 13, 2010 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the Journal of Psychopharmacology has published an original paper showing that ANAVEX 2-73 and its only and active metabolite ANAVEX 19-144 alleviate neurotoxicity and cognition deficits associated with Alzheimer’s disease.…

Dr. Cameron Durrant Named One of PharmaVOICE’s 100 Most Inspiring People in the Pharmaceutical Industry for 2010

Recognized for leadership, innovation in annual ranking of top 100 industry professionals Califon, NJ — August 30, 2010 — Anavex Life Sciences Corp., (“Anavex” or the “Company”) (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company’s Executive Chairman, has been named in this year’s “PharmaVOICE 100” as one of the 100 most…

Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs, Regulatory Strategies in Alzheimer’s Disease

Califon, NJ/Basel, Switzerland/Dresden, Germany – August 10, 2010 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced that it has signed a definitive master services agreement with Genesis BioPharma Group (“Genesis”) and ABX-CRO Advanced Pharmaceutical Services (“ABX-CRO”) to begin clinical studies and regulatory filings  for ANAVEX 2-73, its lead compound for the treatment of…